Nintedanib Stada (Nintedanib)

Nintedanib blocks several receptor tyrosine kinases—VEGFR, PDGFR and FGFR. Inhibiting these receptors reduces angiogenesis, fibroblast proliferation, and extracellular matrix production, which together help limit fibrotic tissue formation and tumor vascularization.

The prescribed dose of Nintedanib is determined by the treating physician based on the specific indication, patient characteristics, and tolerability. Clinicians follow approved labeling and adjust the regimen as needed, but exact dosing details should always be obtained from the prescriber.

Safety data for Nintedanib during pregnancy and lactation are limited. It should only be used when the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain needs) and required import documentation.

The primary alternative for idiopathic pulmonary fibrosis is pirfenidone, another antifibrotic agent. While both aim to slow lung function decline, Nintedanib targets multiple tyrosine kinases, offering broader inhibition of angiogenic and fibrotic pathways, whereas pirfenidone works mainly through anti‑inflammatory and antioxidant mechanisms. Choice depends on patient tolerance, comorbidities and physician judgment.

Nintedanib Stada tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original container, protect it from moisture and direct sunlight, and ensure the package remains tightly closed until use.

Nintedanib is taken orally, usually with food to lessen gastrointestinal discomfort. The tablets are swallowed whole with a glass of water and should be taken at the same time each day as directed by the prescriber.

Serious risks include hepatotoxicity (significant liver enzyme elevation or liver failure), severe bleeding events such as gastrointestinal or pulmonary hemorrhage, and cardiovascular complications like arterial thromboembolism or myocardial infarction. Patients should be monitored regularly for these events.

Nintedanib is contraindicated in patients with known hypersensitivity to the drug, those with active severe liver disease, uncontrolled bleeding disorders, or recent arterial thrombotic events. Caution is also advised for individuals on strong CYP3A4 inhibitors or anticoagulant therapy.